** Deutsche Bank stays cautious about the European pharmaceutical sector, expecting "the sector malaise" to persist due to political headwinds in the U.S.
** It says that "things have got a little slipperier" for the sector's outlook, though there may also be opportunities
** It adds that while the pan-European index .STOXX is up YTD, the pharma sub-sector .SXDP has fallen, with large pharma down by mid-single digits
** If excluding Novo Nordisk NOVOb.CO, the pharma sector performance would have been slightly better, it says
** Novo Nordisk's shares have fallen 29% YTD
COMPANY | RATING | OLD RATING | PT | OLD PT |
|---|---|---|---|---|
Argenx ARGX.BR | Buy | Hold | EUR 550 | EUR 525 |
Swedish Orphan Biovitrum SOBIV.ST | Hold | Sell | SEK 285 | - |
Curevac CVAC.O 5CV.DE | Hold | - | $5.46 | $3.50 |
Roche ROG.S | Sell | - | CHF 235 | CHF 250 |
Sandoz SDZ.S | Buy | - | CHF 48 | CHF 42 |
Zealand Pharma ZELA.CO | Hold | - | DKK 400 | DKK 485 |
(Reporting by Marta Serafinko in Gdansk)
((Marta.Serafinko@thomsonreuters.com; +48 58 769 66 00;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.